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OBJECTIVES To define the cellular mechanisms responsible for the development of life-threatening
arrhythmias in response to sympathetic activity in the congenital and acquired long QT
syndromes (LQTS).
METHODS Transmembrane action potentials (AP) from epicardial (EPI), M and endocardial (ENDO)
cells and a transmural electrocardiogram were simultaneously recorded from an arterially
perfused wedge of canine left ventricle. We examined the effect of beta-adrenergic agonists
and antagonists on action potential duration (APD90), transmural dispersion of repolarization
(TDR) and the development of Torsade de Pointes (TdP) in models of LQT1, LQT2 and
LQT3 forms of LQTS.
RESULTS IKs block with chromanol 293B (LQT1) homogeneously prolonged APD90 of the three cell
types without increasing TDR. Addition of isoproterenol prolonged QT and APD90 of M
but abbreviated that of EPI and ENDO, causing a persistent increase in TDR; Torsade de
Pointes developed or could be induced only in the presence of isoproterenol. IKr block with
d-sotalol (LQT2) and augmentation of late INa with ATX-II (LQT3) prolonged APD90 of
M more than EPI and ENDO, causing increases in QT and TDR. TdP developed in the
absence of isoproterenol. In LQT2 isoproterenol initially prolonged, then abbreviated, the
APD90 of M but always abbreviated EPI, thus transiently increasing TDR and the incidence
of TdP. In LQT3, isoproterenol always abbreviated APD90 of the three cell types, causing a
persistent decrease in TDR and suppression of TdP. The arrhythmogenic as well as protective
actions of isoproterenol were reversed by propranolol.
CONCLUSIONS Our data suggest that beta-adrenergic stimulation induces TdP by increasing transmural
dispersion of repolarization in LQT1 and LQT2 but suppresses TdP by decreasing dispersion
in LQT3. The data indicate that beta-blockers are protective in LQT1 and LQT2 but may
facilitate TdP in LQT3. (J Am Coll Cardiol 2000;35:778–86) © 2000 by the American
College of Cardiology
The congenital long QT syndrome (LQTS) is an hereditary
disorder characterized by a prolonged QT interval in the
electrocardiogram (ECG), commonly associated with an
atypical polymorphic ventricular tachycardia known as Tor-
sade de Pointes (TdP) (1–7). Genetic studies have identified
five gene mutations on chromosomes 3, 7, 11 and 21 as
responsible for the congenital long QT syndrome (8,9).
Mutations in KvLQT1 and minK (KCNE1) are responsible
for defects in the slowly activating delayed rectifier potas-
sium current (IKs), which underlies the LQT1 and LQT5
forms of LQTS, whereas mutations in HERG and KCNE2
are responsible for defect in the rapidly activating compo-
nent of the delayed rectifier potassium current (IKr), which
underlies the LQT2 and LQT6 (10). A mutation in
SCN5A causes an increase in late sodium current (late INa)
which is responsible for LQT3. Congenital forms of LQTS
have been shown to be exquisitely sensitive to increased
sympathetic nervous system activity or to exogenously admin-
istered catecholamines. Indeed, an imbalance of sympathetic
inputs to the heart was at one time thought to underlie the
syndrome (1–4). Accordingly, beta-adrenergic blockade has
long been accepted as front line therapy for LQTS.
Preliminary clinical reports suggest differences in the
sensitivity of LQT1, LQT2 and LQT3 to beta-adrenergic
stimuli (11). Experimental studies employing isolated
guinea pig myocytes also suggest differences in the effect of
isoproterenol on action potential duration (APD) in phar-
macologic models that mimic LQT2 (dofetilide) and LQT3
(anthopleurin A) (12).
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Recent studies from our laboratory examined the electro-
physiologic, electrocardiographic and pharmacologic char-
acteristics of the LQT1, LQT2 and LQT3 syndromes using
arterially-perfused canine left ventricular wedge prepara-
tions, in which we are able to simultaneously record trans-
membrane activity from epicardial, M and endocardial or
Purkinje sites together with a pseudo-ECG along the same
axis, permitting correlation of transmembrane and ECG
activity (13–18). The wedge preparation is capable of
developing and sustaining a variety of arrhythmias, includ-
ing TdP. The pharmacologic models mimicked the clinical
congenital syndromes with respect to prolongation of the
QT interval, T wave morphology, rate dependence of
repolarization and response to antiarrhythmic drugs (14–
18). Using this model, we recently demonstrated the deter-
mining role of beta-adrenergic stimuli in the development
of transmural dispersion of repolarization (TDR) and TdP
in a model of LQT1 (15). This study uses the wedge
preparation to define the role of beta-adrenergic stimuli and
elucidate their cellular mechanisms under conditions mim-
icking the LQT1, LQT2 and LQT3 forms of the congen-
ital LQTS.
METHODS
Arterially perfused wedge of canine left ventricle. Dogs
weighing 20–25 kg were anticoagulated with heparin and
anesthetized with pentobarbital (30–35 mg/kg, IV). The
chest was opened via a left thoracotomy, the heart excised,
placed in a cardioplegic solution consisting of cold (4°C) or
room temperature Tyrode’s solution containing 8.5 mmol/L
[K1]o. Transmural wedges with dimensions of approxi-
mately 2 3 1.5 3 0.9 cm to 3 3 2 3 1.5 cm were dissected
from the left ventricle. The tissue was cannulated via a small
(diameter ;100 mm) native branch of left descending
coronary artery and perfused with cardioplegic solution.
Unperfused tissue, readily identified by its maintained red
appearance (erythrocytes not washed away) was carefully
removed using a razor blade. The preparation was then
placed in a small tissue bath and arterially perfused with
Tyrode’s solution of the following composition (mmol/L):
129 NaCl, 4 KCl, 0.9 NaH2PO4, 20 NaHCO3, 1.8 CaCl2,
0.5 MgSO4, 5.5 glucose, buffered with 95% O2 and 5%
CO2 (37 6 1°C). The perfusate was delivered to the artery
by a roller pump (Cole Parmer Instrument Co., Niles,
Illinois). Perfusion pressure was monitored with a pressure
transducer (World Precision Instruments, Inc., Sarasota,
Florida) and maintained between 40 and 50 mm Hg by
adjustment of the perfusion flow rate. The preparations
remained immersed in the arterial perfusate, which was
allowed to rise to a level 2 to 3 mm above the tissue surface
when possible. To facilitate impalement with the floating
microelectrodes, in some experiments the bath solution was
brought to a level just shy of the top of the wedge and the
chamber was covered to the extent possible so as to avoid a
temperature gradient between the top and lower segments
of the wedge. Preparations displaying significant ST seg-
ment elevation or depression, or in which temperature
gradients were evident along the length of the preparation,
were excluded from the study.
Recordings of a transmural ECG and transmembrane
action potentials. The ventricular wedges were allowed to
equilibrate in the tissue bath until electrically stable, usually
1 h, and stimulated using bipolar silver electrodes insulated
except at the tips and applied to the endocardial surface
(S1).
A transmural ECG was recorded using 3 M KCL-Agar
electrodes (1.1 mm, internal diameter). The electrodes were
placed in the Tyrode’s solution bathing the preparation, 1.0
to 1.5 cm from the epicardial and endocardial surfaces of the
preparation, along the same vector as the transmembrane
recordings (Epicardium: “positive” pole). The electrical field
of the preparation as a whole was measured using this
technique. Thus, the electrocardiographic registration rep-
resents a pseudo-ECG of that part of the left ventricle. To
differentiate it from local electrogram activity, we refer to it
as an ECG in the remainder of the text.
Transmembrane action potentials were simultaneously
recorded from the epicardial, M and endocardial sites using
three to four separate intracellular floating microelectrodes
(direct current resistance: 10 to 20 M_; 2.7 mol/L KCl).
Epicardial and endocardial action potentials were recorded
from the epicardial and the endocardial surfaces of the
preparations at positions approximating the transmural axis
of the ECG recording. M cell action potentials were
recorded at the site along the same axis at which APD was
longest.
All amplified signals were digitized, stored on magnetic
media and CD and analyzed using Spike 2 (Cambridge
Electronic Design, Cambridge, United Kingdom).
Abbreviations and Acronyms
APD 5 action potential duration
APD90 5 action potential duration measured at 90%
repolarization
APD100 5 APD measured at full repolarization
BCL 5 basic cycle length
EAD 5 early afterdepolarization
ECG 5 electrocardiogram
Icl(ca) 5 calcium activated chloride current
Ikr 5 rapidly activating delayer rectifier current
Iks 5 slowly activating delayed rectifier current
INa-Ca 5 Na
1/Ca21 exchange current
late INa 5 late sodium current
LQTS 5 long QT syndrome
PES 5 programmed electrical stimulation
S1 5 basic stimuli
S2 5 premature stimuli
TdP 5 Torsade de Pointes
TDR 5 transmural dispersion of repolarization
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Study protocols. The IKs blocker, chromanol 293B (30
mmol/L), was used to create a model of LQT1 (15), the IKr
blocker, d-sotalol (100 mmol/L), was used to mimic the
LQT2 syndrome (14) and ATX-II (20 nmol/L), an agent
that augments late INa, was used to generate a model of
LQT3 (14,18). The validity of these pharmacologic models
as surrogates for the congenital syndromes was previously
demonstrated in myocyte (12), perfused wedge (14–18) and
in vivo studies (19,20).
We routinely examined:
1) the influence of isoproterenol (50–100 nmol/L), a beta-
adrenergic agonist, on the QT interval, the APD and
TDR (LQT1: n 5 10, LQT2: n 5 8, LQT3: n 5 8),
2) the dose-dependent effects of propranolol (0.1, 0.3, 1.0,
3.0 mmol/L) in the absence of isoproterenol (LQT1: n 5
8, LQT2: n 5 6, LQT3: n 5 6), and
3) the effects of propranolol (0.5–1.0 mmol/L) to suppress
the influence of isoproterenol (LQT1: n 5 10, LQT2:
n 5 8, LQT3: n 5 8).
Control measurements were obtained after approximately
1 h of equilibration. The chromanol 293B, d-sotalol and
ATX-II data were collected for a period of up to 1 h starting
1 h after addition of the respective drug. The effect of
isoproterenol was recorded at 2 and 10 min, approximating
the maximal and steady state influence of the catechol-
amine, respectively. A steady-state was achieved within
5–7 min. Propranolol data were recorded after 20 min of
exposure to each concentration of drug.
Action potential duration was measured at 90% repolar-
ization (APD90). Transmural dispersion of repolarization
(TDR) was defined as the difference between the longest
and the shortest repolarization time (activation time 1
APD90) of transmembrane action potentials recorded across
the wall (M cell 2 epicardial cell). The QT interval was
defined as the time between QRS onset and the point at
which the final downslope of the T wave crossed the
baseline. In all figures, graphic correlation of transmem-
brane and electrocardiographic activity was achieved by
dropping a dotted line from the point of full repolarization
of each action potential (APD100-approximated by eye) to
the ECG trace.
The development of spontaneous as well as programmed
electrical stimulation (PES)-induced TdP was assessed in
the absence of any drugs (control), in the presence of
chromanol 293B, d-sotalol or ATX-II alone and after
further addition of isoproterenol (2 min and 10 min),
propranolol or a combination of the two agents. Pro-
grammed electrical stimulation-induced arrhythmias were
evaluated using single extrastimuli (S2) applied to the
epicardial surface of the wedge.
Statistics. Statistical analysis of the data was performed
using a Student t test for paired data or Analysis of Variance
coupled with Scheffe’s test, as appropriate. Data are ex-
pressed as mean 6 SD values, except for those shown in the
figures, which are expressed as mean 6 SEM values.
Significance was defined as a p , 0.05.
RESULTS
Effect of chromanol 293B, d-sotalol and ATX-II on QT
interval, APD and dispersion of repolarization. Table 1
shows effects of chromanol 293B (LQT1 model), d-sotalol
(LQT2 model) and ATX-II (LQT3 model) alone on the
QT interval, the APD90 of the endocardial, M and epicar-
dial cells and TDR at a BCL of 2,000 msec. The APD90 of
the endocardial cell was always between that of the M cell
and epicardial cell. Chromanol 293B (30 mmol/L) produced
a homogeneous prolongation of APD90 of the three cell
types, thus prolonging the QT interval with no major
change in the width of the T wave or TDR (Fig. 1, 4A and
4B). d-Sotalol (100 mmol/L) produced a preferential pro-
longation of APD90 of the M cell, thus causing an increase
in the QT interval and TDR (Fig. 2, 4C and 4D). ATX-II
(20 nmol/L) also preferentially prolonged the APD90 of the
M cell, although the APD90 of all transmural sites pro-
longed more than with d-sotalol, resulting in a delay in the
appearance of the T wave and a dramatic increase in the QT
interval and TDR (Fig. 3, 4E and 4F).
Differential effect of isoproterenol in the LQT1, LQT2
and LQT3 models. The influence of isoproterenol in the
LQT1 model is illustrated in Figure 1. Shown are super-
imposed action potentials recorded simultaneously from M
Table 1. Effects of Chromanol 293B, d-Sotalol and ATX-II on the QT Interval, APD90 and
Transmural Dispersion of Repolarization in Perfused Wedge Preparations
QT
APD90
(Endo)
APD90
(M Cell)
APD90
(Epi) TDR
Control 308 6 12 266 6 22 282 6 14 227 6 18 43 6 10
Chromanol 293B (30 mM) 387 6 11* 343 6 19* 360 6 12* 300 6 10* 47 6 9
Control 310 6 13 265 6 21 285 6 12 228 6 16 44 6 9
d-Sotalol (100 mM) 383 6 15* 345 6 23* 359 6 14* 272 6 15* 74 6 12*
Control 312 6 14 268 6 20 287 6 12 228 6 15 45 6 9
ATX-II (100 nM) 552 6 39* 494 6 43* 530 6 36* 375 6 30* 142 6 29*
APD90 5 action potential duration at 90% repolarization; Endo 5 endocardial cell; Epi 5 epicardial cell; QT 5 QT interval;
TDR 5 transmural dispersion of repolarization.
*p , 0.0005 vs. control.
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and epicardial cells, together with a transmural ECG at a
BCL of 2,000 msec. In all cases, the peak of the T wave in
the ECG was coincident with the repolarization of epicar-
dium, whereas the end of the T wave was coincident with
the repolarization of the M region. Thus, TDR across the
ventricular wall was defined as the difference in the repo-
larization time between the M cell and epicardial cell. In the
presence of 30 mmol/L chromanol 293B, which alone
produced a homogeneous prolongation of APD with no
major change in the width of the T wave or in TDR,
isoproterenol (100 nmol/L) dramatically prolonged the QT
interval and the APD of the M cell, but abbreviated that of
the epicardial cell, resulting in a persistent increase in TDR
and in a widening of the T wave, as commonly seen in
LQT1 patients. Composite data of the influence of isopro-
terenol in the LQT1 model is shown in Figure 4, A and B.
Figure 2 illustrates the influence of isoproterenol in the
LQT2 model. After a preferential prolongation of the M
cell action potential and an increase in TDR by 100 mmol/L
d-sotalol, isoproterenol (100 nmol/L) initially prolonged
(2 min) and then abbreviated the QT interval and the APD
of the M cell to the control level (10 min), whereas the APD
of the epicardial cell was always abbreviated, resulting in a
transient increase in TDR. Composite data of the influence
of isoproterenol in the LQT2 model is shown in Figure 4, C
and D.
The effect of isoproterenol in the LQT3 model is
illustrated in Figure 3. ATX-II 20 nmol/L alone produced
a dramatic prolongation of the M cell action potential and
a more modest prolongation of the APD of epicardium,
resulting in a dramatic increase in TDR. Isoproterenol (100
nmol/L) produced a persistent abbreviation of the QT
interval and the APD of both cells, resulting in a persistent
decrease of TDR. Composite data of the influence of
isoproterenol in the LQT3 model is shown in Figure 4, E
and F.
In four preparations, we examined the influence of
isoproterenol (100 nmol/L) alone on transmembrane and
ECG activity. Isoproterenol always abbreviated the APD90
of the three cell types, thus abbreviating the QT interval
Figure 1. Effect of isoproterenol in the LQT1 model. Shown are
superimposed action potentials recorded simultaneously from M
and epicardial cells, together with a transmural ECG. BCL 5
2,000 ms. Chromanol 293B (30 mmol/L) produced a homoge-
neous prolongation of APD of both cell types with no major
change in the width of the T wave or in TDR. Isoproterenol (Iso,
100 nmol/L) in the continued presence of 293B dramatically
prolonged the APD of the M cell (2 min) and maintained it
prolonged as the effect approached a steady state (10 min), whereas
the epicardial action potential was always abbreviated, resulting in
a persistent increase in TDR and in a widening of the T wave, as
commonly seen in LQT1 patients. APD 5 action potential
duration; LQT1 5 long QT syndrome 1; TDR 5 transmural
dispersion of repolarization.
Figure 2. Effect of isoproterenol in the LQT2 model. d-Sotalol
(d-Sot, 100 mmol/L) produced a preferential prolongation of the
M cell APD and an increase in TDR. Isoproterenol (Iso, 100
nmol/L) in the continued presence of d-Sot initially prolonged
(2 min) and then abbreviated the APD of the M cell to the control
level (10 min), whereas the APD of epicardial cell was always
abbreviated, resulting in a transient increase in TDR. APD 5
action potential duration; LQT2 5 long QT syndrome 2; TDR 5
transmural dispersion of repolarization.
Figure 3. Effect of isoproterenol in the LQT3 model. ATX-II (20
nmol/L) produced a marked prolongation of APD of the M cell,
more than that of the epicardial cell and a dramatic increase in
TDR. Isoproterenol (Iso, 100 nmol/L) in the continued presence
of ATX-II always abbreviated the APD of both cells, resulting in
a persistent decrease in TDR. APD 5 action potential duration;
LQT3 5 long QT syndrome 3; TDR 5 transmural dispersion of
repolarization.
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without any major changes in TDR or the development of
TdP.
Effect of propranolol on the QT interval, APD and
dispersion of repolarization. In all three models, thera-
peutic concentrations of propranolol (0.1 to 1 mmol/L) had
little or no effect on the QT interval, APD90 of the three cell
types or TDR. Higher concentrations (3 mmol/L) prefer-
entially abbreviated the QT interval and APD90 of the M
cell, resulting in a significant decrease of TDR, most likely
due to the effect of this concentration of propranolol to
block the late INa, which is intrinsically larger in the M cell
than in the other cell types (21).
Effect of propranolol to suppress the influence of isopro-
terenol. Figure 5 illustrates composite data of the effects of
propranolol (1 mmol/L) to suppress the influence of isopro-
terenol in the three models. Once again, 1 mmol/L pro-
pranolol had little to no effect on the QT interval, APD90 or
TDR in the three models. In LQT1 (Fig. 5, A and B) and
LQT2 (Fig. 5, C and D), propranolol completely suppressed
the effect of isoproterenol (at both 2 and 10 min) to persistently
or transiently prolong the M cell APD90 and thus to increase
TDR. In LQT3 (Fig. 5, E and F), propranolol completely
suppressed the protective effect of isoproterenol (at both 2 and
10 min) to abbreviate the M cell APD90 and to decrease TDR.
Effect of isoproterenol and propranolol on development
of torsade de pointes. Spontaneous as well as stimulation-
induced TdP were observed in the three models (Fig. 6).
Under control conditions and in the presence of chromanol
293B alone (LQT1 model), neither spontaneous nor PES-
induced TdP were observed. In this model, TdP could be
induced only after addition of isoproterenol (at both 2 and
10 min). Propranolol (0.5 or 1 mmol/L) completely inhib-
ited the effect of isoproterenol to induce spontaneous or to
permit the induction of stimulation-induced TdP in the
LQT1 model (Fig. 7A). In the LQT2 and LQT3 models,
TdP occurred in the presence of d-sotalol and ATX-II
alone (Fig. 6, A and B). In the LQT2 model, isoproterenol
transiently increased the incidence of both spontaneous and
stimulation-induced TdP (2 min), due in part to a transient
exaggeration of TDR. At 10 min, the effect of isoproterenol
reversed, approaching control values. Propranolol completely
blocked isoproterenol’s action to increase the incidence of TdP
(Fig. 7B). In contrast to the LQT1 and LQT2 models,
isoproterenol suppressed both spontaneous and stimulation-
induced TdP (at both 2 and 10 min) in the LQT3 model. In
Figure 4. Composite data of the effect of isoproterenol in the LQT1, LQT2 and LQT3 models. In LQT1, isoproterenol (Iso) produced
a persistent prolongation of the APD90 of the M cell and of the QT interval (at both 2 and 10 min), whereas the APD90 of the epicardial
cell was always abbreviated, resulting in a persistent increase in TDR (A and B). In LQT2, isoproterenol initially prolonged (2 min) and
then abbreviated the QT interval and the APD90 of the M cell to the control level (10 min), whereas the APD90 of epicardial cell was
always abbreviated, resulting in a transient increase in TDR (C and D). In LQT3, isoproterenol produced a persistent abbreviation of the
QT interval and the APD90 of both M and epicardial cells (at both 2 and 10 min), resulting in a persistent decrease in TDR (E and F).
*p , 0.0005 vs. control; †p , 0.0005; ††p , 0.005; †††p , 0.05, vs. 293B, d-Sotalol (d-Sot) or ATX-II. APD90 5 action potential
duration measured at 90% repolarization; LQT1, 2, 3 5 long QT syndrome 1, 2, 3; TDR 5 transmural dispersion of repolarization.
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this case, propranolol reversed the protective effect of isopro-
terenol, causing an increase in the incidence of TdP (Fig. 7C).
DISCUSSION
Differential response of LQT1, LQT2 and LQT3 mod-
els to beta-adrenergic stimulation. Although it has long
been appreciated that some forms of congenital and ac-
quired LQTS are exquisitely sensitive to beta-adrenergic
stimulation (1–7), the cellular basis for the arrhythmogenic
actions of the sympathetic nervous system was poorly
understood. Schwartz et al. (11) reported that cardiac events
(sudden death and cardiac arrest) are most often associated
with adrenergic factors, defined as physical and emotional
stress, in patients with the LQT1 genotype than in those
with either the LQT2 or LQT3. Wilde et al. (22) recently
demonstrated that a sudden startle in the form of an
auditory stimulus (alarm clock) is the predominant trigger of
cardiac events in patients with the LQT2 syndrome. Rela-
tively little is known about the effect of the sympathetic
nervous system on TdP in LQT3, except that cardiac events
usually occur at rest or during sleep (11,23).
Beta-adrenergic stimulation with isoproterenol is known
to augment a number of currents, including Ca21-activated
IKs, Ca
21-activated chloride current (ICl[Ca]) (24) and Na
1/
Ca21 exchange current (INa-Ca). The response of APD and
of the QT interval to beta-adrenergic stimulation largely
depends on the shift in net outward current. An increase in
net outward repolarizing current, due to a relatively large
increase of IKs and ICl(Ca) vs. INa-Ca is thought to be
responsible for the abbreviation of APD and QT interval in
response to beta-adrenergic stimulation under normal con-
ditions and for abbreviation of epicardial and endocardial
cell APD under long QT conditions. A defect in IKs
(especially in the M region) could offset this balance and
account for failure of beta-adrenergic stimulation to abbre-
viate APD and QT interval in patients with the LQT1
genotype (5–7,25–27). Among the three transmural cell
types, the M cell has been reported to have an intrinsically
smaller IKs (28).
In the LQT1 model (reduced IKs), isoproterenol prolongs
the APD of the M cell because IKs (outward current) is
reduced to levels at which INa-Ca (inward current) predom-
inates. The presence of higher levels of IKs in epicardial and
endocardial cells (even in the presence of chromanol 293B)
accounts for the effect of the beta-agonist to abbreviate
APD in these cells. The disparate effects of isoproterenol on
the three cell types results in a persistent increase of TDR
and in the development of spontaneous as well as
Figure 5. Composite data of the effect of propranolol (Prop, 1 mmol/L) to suppress the influence of isoproterenol (Iso, 100 nmol/L) on
the QT interval (solid circle), the APD90 of M (open circle) and epicardial (Epi, open triangle) cells and TDR (solid circle) in the LQT1
(A and B), LQT2 (C and D) and LQT3 (E and F) models. In the LQT1 and the LQT2 models, propranolol completely prevented the
influence of isoproterenol to persistently or transiently increase TDR. In the LQT3 model, propranolol completely suppressed the
protective effect of isoproterenol to decrease TDR. The isoproterenol data reported here were recorded 10 min after addition of the
catecholamine although similar results were obtained at 2 min in the presence of propranolol. *p , 0.0005 vs. control. APD90 5 action
potential duration measured at 90% repolarization; LQT1, 2, 3 5 long QT syndrome 1, 2, 3; TDR 5 transmural dispersion of
repolarization.
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stimulation-induced TdP. Our findings in the LQT1 model
are concordant with a high sensitivity of patients with the
LQT1 syndrome to beta-adrenergic stimulation. Cardiac
events in this syndrome often occur during exercise, when
catecholamine levels are maximally elevated.
In the LQT2 model (reduced IKr), isoproterenol tran-
siently prolongs the APD of the M cell, possibly due to a
more rapid increase of INa-Ca than of IKs. The constant
abbreviation of epicardial and endocardial action potentials
is most likely due to higher levels of IKs in these cell types.
As a consequence, TDR and the incidence of TdP are only
transiently increased. The persistent effect of isoproterenol
to abbreviate epicardial and endocardial APD and its
transient effect to prolong the APD of the M cells is also
observed in strips of tissues isolated from the three regions
of the wall following pretreatment with the IKr blocker,
E-4031 (29). Effects similar to those of isoproterenol are
observed in the M cell preparations in response to acceler-
ation of the stimulation rate. These effects are eliminated
after addition of ryanodine or in the presence of low
[Ca21]o, suggesting that the effects are secondary to intra-
cellular Ca21 loading. In isolated M cell, but not endocar-
dial or epicardial, preparations pretreated with E-4031,
acceleration of rate or addition of isoproterenol also tran-
siently induce early afterdepolarization (EAD) activity (29).
Our data are concordant with those of Priori et al. (12) who
demonstrated an effect of isoproterenol to transiently pro-
long APD and induce EADs in guinea pig myocytes
pretreated with the IKr blocker, dofetilide. Taken together,
these findings suggest that beta-adrenergic stimulation con-
tributes to precipitation of TdP in LQT2 by producing a
transient but dramatic increase in TDR and causing induc-
tion of EAD-mediated extrasystoles. The transient nature
of these changes following an increase in sympathetic
activity may explain why cardiac events in LQT2 generally
occur following a startle, especially from a sleep state (alarm
clock, telephone bell or ambulance siren, etc.). Delays in
APD adaptation during sudden arousal reaction is reported
to occur not only in LQTS patients, but also in normal
subjects (30). The presumption is that if TdP does not occur
soon after the surge in sympathetic activity in LQT2
patients, it is unlikely to occur later (22).
In the LQT3 model (increased late INa), isoproterenol
produces a persistent abbreviation of the APD of all three
ventricular cell types. Preferential abbreviation of the M cell
APD results in a persistent decrease of TDR and a decrease
in the incidence of both spontaneous and stimulation-
induced TdP. These effects of isoproterenol are likely due to
an increase of IKs as well as a reduction of the electrogenic
INa-Ca due to a more positive M cell action potential plateau
voltage. Our data suggest that beta-adrenergic stimulation
may protect against cardiac events in patients with the
LQT3 genotype. These findings are consonant with the
observation that patients with the LQT3 syndrome, unlike
those with LQT1 or LQT2, often have cardiac events at rest
or during sleep when sympathetic tone is expected to be low
(11,23).
Differential effect of beta-adrenergic blockade in the
LQT1, LQT2 and LQT3 genotype. Our data indicate
that beta-blockade with propranolol totally suppresses the
development of TdP in the LQT1 model, largely suppresses
it in LQT2 and can induce the arrhythmia in LQT3. These
distinctions are due to the fact that the substrate for reentry
(augmented TDR) appears only after beta-adrenergic stim-
ulation in LQT1, may be present in the absence of sympa-
thetic stimulation, but is greatly amplified by beta-
adrenergic stimulation in LQT2 and is importantly reduced
following sympathetic stimulation in LQT3.
These experimental findings appear to closely mirror the
clinical experience. Beta-blockade has long been considered
Figure 6. Polymorphic ventricular tachycardia displaying features
of Torsade de Pointes (TdP) in the LQT2 (A) and the LQT3 (B)
models of arterially-perfused canine left ventricular wedge prepa-
rations. Each trace shows action potentials simultaneously re-
corded from M and epicardial (Epi) cells together with a trans-
mural ECG. The preparation was paced from the endocardial
surface at a BCL of 1,000 or 2,000 msec (S1). A: Spontaneous
TdP induced in the LQT2 (d-Sotalol) model. The long episode of
TdP (fourth group) was preceded by salvos of three consecutive
beats (first group) and an isolated ventricular premature beat (third
group), similar to the clinical experience. B: Stimulation-induced
TdP in the LQT3 (ATX-II) model. ATX-II produced very
significant dispersion of repolarization (first grouping). A single
extrastimulus (S2) applied to the epicardial surface initiated TdP
(second grouping). LQT1, 2 5 long QT syndrome 1, 2.
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as a first-line therapy in patients with congenital LQTS
(1–7). Patients with the LQT1 genotype are highly respon-
sive to beta-adrenergic blocking agents (31). Beta-blockers
are also effective in suppressing cardiac events in patients
with the LQT2 genotype (22). The effectiveness of beta-
blockers in patients with the LQT3 genotype is not well
defined because of the rarity of the syndrome, although
events generally occur at rest or during sleep, when heart
rate is relatively slow (11). Both clinical (23) and experi-
mental (12,14) studies have demonstrated that LQT3 dis-
plays a much steeper QT- and APD-rate relation than
either LQT1 or LQT2. Thus, the substrate for reentry
rapidly dissipates as heart rate is accelerated in LQT3 and
reappears as heart rate is slowed. Our data of a protective
effect of isoproterenol in LQT3, when coupled with the
rate-slowing effect of the beta-blockers, suggest that beta-
blockade might be contraindicated in LQT3. A test of this
hypothesis clearly must await appropriate clinical trials.
Study limitations. Our interpretations of the data are
based on the assumption that the activity recorded from the
cut surface of the perfused wedge preparation is represen-
tative of cells within the respective layers of the wall
throughout the wedge. Such validation was provided in
three previous studies employing the perfused wedge prep-
aration (14,17,18).
The extent to which our pharmacologic models mimic
the three forms of congenital long QT syndrome is also
important. We believe that these pharmacologic models
provide reasonable surrogates for the respective clinical
syndromes because the behavior of the models mimics the
clinical observations with respect to the electrocardiographic
changes in the morphology and appearance of the T wave
(32,33), rate dependence of the QT interval (23) and
response to pharmacologic agents (23,31).
Finally, extrapolation of the experimental data to the
clinic must be approached with great caution for obvious
reasons. It is our hope that these findings will prove helpful
in the design of clinical trials to test the hypotheses
suggested by the study.
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